Forthright Family Wealth Advisory LLC Invests $45,000 in CEL-SCI Co. (NYSE:CVM)

Forthright Family Wealth Advisory LLC bought a new position in shares of CEL-SCI Co. (NYSE:CVM) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 16,500 shares of the company’s stock, valued at approximately $45,000.

A number of other large investors also recently modified their holdings of CVM. Vontobel Holding Ltd. acquired a new position in shares of CEL-SCI during the fourth quarter worth approximately $68,000. Sheets Smith Wealth Management acquired a new position in CEL-SCI in the fourth quarter valued at approximately $54,000. Thoroughbred Financial Services LLC lifted its holdings in CEL-SCI by 24.6% in the fourth quarter. Thoroughbred Financial Services LLC now owns 126,761 shares of the company’s stock valued at $344,000 after buying an additional 25,000 shares during the period. D.A. Davidson & CO. lifted its holdings in CEL-SCI by 564.2% in the fourth quarter. D.A. Davidson & CO. now owns 290,928 shares of the company’s stock valued at $791,000 after buying an additional 247,128 shares during the period. Finally, Tower Research Capital LLC TRC lifted its holdings in CEL-SCI by 2,011.9% in the fourth quarter. Tower Research Capital LLC TRC now owns 16,198 shares of the company’s stock valued at $44,000 after buying an additional 15,431 shares during the period. 12.08% of the stock is currently owned by institutional investors and hedge funds.

CEL-SCI Trading Up 0.8 %

NYSE CVM traded up $0.01 during trading hours on Friday, hitting $1.30. The company’s stock had a trading volume of 147,545 shares, compared to its average volume of 236,388. CEL-SCI Co. has a twelve month low of $1.04 and a twelve month high of $3.23. The company has a quick ratio of 1.18, a current ratio of 1.67 and a debt-to-equity ratio of 0.63. The firm has a market capitalization of $70.41 million, a P/E ratio of -2.06 and a beta of 1.04. The stock has a fifty day moving average of $1.42 and a 200 day moving average of $2.06.

CEL-SCI (NYSE:CVM) last issued its earnings results on Thursday, May 16th. The company reported ($0.14) EPS for the quarter, meeting the consensus estimate of ($0.14). Equities research analysts forecast that CEL-SCI Co. will post -0.51 earnings per share for the current fiscal year.

Insider Buying and Selling at CEL-SCI

In other news, CEO Geert R. Kersten bought 30,000 shares of the stock in a transaction on Wednesday, May 8th. The stock was purchased at an average price of $1.39 per share, with a total value of $41,700.00. Following the completion of the purchase, the chief executive officer now owns 1,195,309 shares of the company’s stock, valued at $1,661,479.51. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. In related news, CEO Geert R. Kersten acquired 30,000 shares of the stock in a transaction dated Wednesday, May 8th. The stock was bought at an average price of $1.39 per share, with a total value of $41,700.00. Following the completion of the transaction, the chief executive officer now directly owns 1,195,309 shares of the company’s stock, valued at $1,661,479.51. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Robert Eugene Watson acquired 20,000 shares of the stock in a transaction dated Wednesday, May 8th. The shares were bought at an average cost of $1.39 per share, with a total value of $27,800.00. Following the transaction, the director now directly owns 24,431 shares of the company’s stock, valued at $33,959.09. The disclosure for this purchase can be found here. Over the last 90 days, insiders bought 58,000 shares of company stock valued at $80,620. Corporate insiders own 16.24% of the company’s stock.

Analysts Set New Price Targets

Separately, StockNews.com lowered shares of CEL-SCI from a “hold” rating to a “sell” rating in a report on Friday, March 15th.

CEL-SCI Profile

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers.